1. Home
  2. RYTM vs TDS Comparison

RYTM vs TDS Comparison

Compare RYTM & TDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • TDS
  • Stock Information
  • Founded
  • RYTM 2008
  • TDS 1968
  • Country
  • RYTM United States
  • TDS United States
  • Employees
  • RYTM N/A
  • TDS N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • TDS Telecommunications Equipment
  • Sector
  • RYTM Health Care
  • TDS Telecommunications
  • Exchange
  • RYTM Nasdaq
  • TDS Nasdaq
  • Market Cap
  • RYTM 4.3B
  • TDS 3.9B
  • IPO Year
  • RYTM 2017
  • TDS N/A
  • Fundamental
  • Price
  • RYTM $61.99
  • TDS $33.21
  • Analyst Decision
  • RYTM Strong Buy
  • TDS Buy
  • Analyst Count
  • RYTM 12
  • TDS 2
  • Target Price
  • RYTM $76.75
  • TDS $50.00
  • AVG Volume (30 Days)
  • RYTM 525.0K
  • TDS 742.4K
  • Earning Date
  • RYTM 08-05-2025
  • TDS 08-01-2025
  • Dividend Yield
  • RYTM N/A
  • TDS 0.48%
  • EPS Growth
  • RYTM N/A
  • TDS N/A
  • EPS
  • RYTM N/A
  • TDS N/A
  • Revenue
  • RYTM $136,863,000.00
  • TDS $4,856,000,000.00
  • Revenue This Year
  • RYTM $37.56
  • TDS N/A
  • Revenue Next Year
  • RYTM $74.99
  • TDS $0.40
  • P/E Ratio
  • RYTM N/A
  • TDS N/A
  • Revenue Growth
  • RYTM 48.88
  • TDS N/A
  • 52 Week Low
  • RYTM $39.46
  • TDS $17.90
  • 52 Week High
  • RYTM $69.89
  • TDS $41.21
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 47.67
  • TDS 42.77
  • Support Level
  • RYTM $60.70
  • TDS $33.19
  • Resistance Level
  • RYTM $62.65
  • TDS $33.89
  • Average True Range (ATR)
  • RYTM 2.39
  • TDS 0.92
  • MACD
  • RYTM -0.52
  • TDS -0.11
  • Stochastic Oscillator
  • RYTM 14.04
  • TDS 2.91

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About TDS Telephone and Data Systems Inc.

Telephone and Data Systems Inc is a diversified telecommunications operator that provides mobile, telephone, and broadband services. The company's segments include UScellular Wireless, UScellular Towers, and TDS Telecom. It generates maximum revenue from the UScellular Wireless segment.

Share on Social Networks: